Navigation Links
NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets

LAWRENCE, Mass., May 7 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its wholly-owned subsidiary, Medisystems Corporation, has entered into a new supply and distribution agreement with Kawasumi Laboratories, Inc. regarding Kawasumi's continued supply of blood tubing sets to Medisystems through January 31, 2010.

"We are pleased to extend our long-standing relationship with Kawasumi for blood tubing sets," said Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "I believe NxStage is well positioned to preserve and build upon Medisystems' reputation for high quality and to grow the business further with new and innovative products for our customers. This is another significant agreement that we have successfully renewed since acquiring the company. I am pleased with the progress that we continue to see in this business."

Headquartered in Tokyo, Japan, Kawasumi Laboratories, Inc. has been providing high quality medical supplies worldwide since 1957. Kawasumi has been a pioneer in plastic molding technologies in Japan and has grown its proprietary manufacturing know-how in the markets of medical devices and pharmaceuticals.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated benefits of the Company's new agreement with Kawasumi, the expected performance of the Medisystems' business, and the development of new and innovative products. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2007. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Investor Relations Contact

Stephanie Marks for NxStage


SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc.
2. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
3. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
4. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
5. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
6. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
7. NxStage Medical Reports Third Quarter 2007 Results
8. NxStage Medical Completes Acquisition of Medisystems
9. Derma Sciences Announces Date of Its First Quarter 2008 Earnings Release and Conference Call on May 15, 2008
10. Vail Valley Medical Center Board of Directors Announces Appointment of New President & CEO, John Cassin
11. American Heart Association Announces Next New Journal - Circulation: Heart Failure Set for May Premier
Post Your Comments:
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: